Tian Yong Zheng

Dr. Tian Yong Zheng is a science law clerk and registered patent agent in Goodwin’s Life Sciences IP practice group. Dr. Zheng began her career in patent prosecution in 2020 and joined Goodwin in 2025. She assists clients with a range of intellectual property matters related to life sciences innovations, including patent preparation, patent prosecution, IP due diligence, and freedom-to-operate analysis. 

Dr. Zheng is registered with the U.S. Patent and Trademark Office only; her work is supervised by DC-barred partners at Goodwin. 

Dr. Zheng has worked with clients across a broad range of life sciences technologies, including antibodies, CAR-T cell therapies, genome therapies, and next-generation sequencing (NGS). As a scientist, Dr. Zheng conducted genetic engineering research for biofuel production in microbial systems and has published over 10 peer-reviewed articles. 

• Supported Takara Bio, a global biotechnology and life sciences company headquartered in Shiga, Japan, with its acquisition of Curio Bioscience, a pioneering company in the field of spatial genomics* 
• Provided IP support in ARCH Venture Partners’ co-leadership of a $1 billion Series A funding round in Xaira Therapeutics* 
• Conducted IP due diligence for the underwriters of Aardvark Therapeutics in its $94.2 million initial public offering (IPO)* 
• Conducted IP due diligence for the underwriters of argenx SE in its $1.27 billion follow-on offering* 

*Denotes experience prior to joining Goodwin